Community Practice Connections®: Medical Crossfire®: Crossroads in Advanced RCC Decision- Making: With Many Options, How Will You Treat Your Patient Today?... And Tomorrow?

Community Practice Connections®: Medical Crossfire®: Crossroads in Advanced RCC Decision- Making: With Many Options, How Will You Treat Your Patient Today?... And Tomorrow? is organized by Physicians' Education Resource, LLC (PER) and will be held from Mar 29, 2019 - Mar 29, 2020.

Target Audience:
This educational program is directed toward medical oncologists, surgical oncologists, radiation oncologists, and urologists involved in the treatment of RCC. Nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with RCC are also invited to participate.

Accreditation:
• CME: 2.0

Activity Overview:
This is a case-based, interactive, online CME activity based on a live symposium that was held adjunct to the 2019 Genitourinary Cancers Symposium in San Francisco. Clinical decision-making in the setting of metastatic renal cell carcinoma (mRCC) has been undergoing dramatic change. The approval of new systemic agents has expanded the lines of therapy available to patients, and raised questions about how rational treatment planning and effective sequencing of new and older standards of care can optimize patient outcomes. Additionally, the benefit of real-world experience and data from subgroup analyses and long-term follow-up of landmark clinical trials continue to refine treatment strategies in RCC.

This program consists of a series of interactive clinical vignettes and short video interviews with leading experts in renal cell carcinoma (RCC). The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Explain the biologic factors that drive renal cell carcinoma (RCC) and provide the rationale for using targeted agents and immunotherapies as single agents and in combination
• Evaluate practice-changing and emerging data from RCC clinical trials across the advanced disease continuum
• Apply best practices to proactively identify and mitigate treatment-related toxicities related to therapy for metastatic RCC
• Integrate knowledge of patient characteristics, as well as the efficacy and safety of single-agent and combination systemic therapies, into clinical decision-making for patients with metastatic RCC

Additional details will be posted as soon as they are available.